Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

The BRAVE study is perhaps the closest thing Amarin has to a possible home run. I hope you're right that there must be some positive results or it would have been halted. These days, I'm prone to think everything ends poorly for Amarin, whether it's court cases or trials or efforts to promote Vascepa.

If the BRAVE results are positive, it's fortunate that the trial's principal investigator is Cynthia Carlsson, clinical core leader of the Wisconsin Alzheimer’s Disease Research Center.

As it turns out, she was named late last year as the new Chair of the U.S. Department of Health and Human Services Advisory Council on Alzheimer's Research, Care and Services. It's a two-year post so it means she'll be holding this influential position at the time that the BRAVE results are announced next year, assuming the study doesn't get delayed for another year. The national council's mandate is to create a national strategic plan to address the rapidly escalating Alzheimer's dementia crisis.

Part of the Advisory Council's responsibility is to carry out the National Alzheimer's Project Act's task of accelerating the development of treatments for Alzheimer's disease and related dementias and coordinating with international efforts to fight these conditions.

So if the study results are positive, I think you'll see the share price of Amarin skyrocket to heights you really can't imagine and the results will be widely respected because the study was carried out under the supervision of a doctor so highly respected that she was made the chairperson of this influential advisory council.